OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder’s Meeting
22 Juni 2023 - 6:00PM
Business Wire
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) today announced that all the resolutions submitted to a
vote at the Combined General Shareholders’ Meeting were approved as
proposed by OSE Immunotherapeutics’ Board of Directors.
The results of each resolution voted on can be found on the
Company’s website in the “Investor – General Shareholders’ Meeting”
section:
https://ose-immuno.com/en/general-shareholders-meetings/
In total, the shareholders who participated in person, by proxy
to the chairwoman, by proxy to a third party or by postal vote
owned 5,870,122 shares representing 10,762,646 votes, i.e. 30.8% of
the share capital and 42.8% of the voting rights.
The Combined Shareholders’ Meeting approved all the resolutions
proposed by the Board of Directors.
The shareholders approved the annual and consolidated financial
statements as of December 31, 2022.
They approved the appointment of Eric Leire as a new independent
Director, of Nicolas Poirier*, Chief Executive Officer of OSE
Immunotherapeutics, as Director and of Anne-Laure Autret-Cornet,
Chief Financial Officer, as Director representing the employee
shareholders. The Combined Shareholders’ Meeting has also renewed
the term of office of Pr. Brigitte Dréno and Pr. Gérard Tobelem as
independent Directors.
“On behalf of the Board of Directors and OSE’s team, I wish to
warmly thank Jean-Patrick Demonsang for his expertise, his
commitment and his achievements throughout his director’s terms. As
part of its succession plan, the Board wanted to strengthen the
expertise and international dynamics to support the Company’s
growth and we are very happy to welcome Eric Leire, French and
American medical doctor and entrepreneur. His American and
international experience in biotech and pharma industry fits
perfectly into our growth strategy”, comments Dominique Costantini,
Chairwoman of OSE Immunotherapeutics.
« I am very honored to join OSE’s Board and I thank the
Directors for their confidence. I will be happy to support the
Management team and to contribute to the international Company’s
development and growth strategy to further establishing OSE as a
recognized biotech leader in immunotherapy,” adds Eric Leire.
The Board of Directors of OSE Immunotherapeutics now includes
the 10 following members:
- Dominique Costantini, Chairwoman - Maryvonne Hiance,
Vice-Chairwoman - Anne-Laure Autret-Cornet, Director representing
the employee shareholders and Chief Financial Officer - Elsy
Boglioli, independent Director - Brigitte Dréno, independent
Director - Didier Hoch, independent Director - Alexandre Lebeaut,
independent Director - Eric Leire, independent Director - Nicolas
Poirier, Director and Chief Executive Officer - Gérard Tobelem,
independent Director
* Nicolas Poirier, previously Director representing the employee
shareholders, resigned with effect at the General Shareholders’
Meeting approving the 2022 financial statements, further to his
appointment as Chief Executive Officer on October 7, 2022.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company dedicated to
developing first-in-class assets in immuno-oncology and
immuno-inflammation.
The Company’s current well-balanced first-in-class clinical
pipeline includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or
lymphomas (first patient included). OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on
CD47/SIRPα pathway) developed in partnership with Boehringer
Ingelheim in advanced solid tumors; positive Phase 1 dose
escalation results in monotherapy and in combination, in particular
with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing
clinical trial in combination with ezabenlimab alone or with other
drugs in patients with recurrent/metastatic head and neck squamous
cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).
OSE Immunotherapeutics expects to generate further significant
value from its two proprietary drug discovery platforms, which are
central to its ambitious goal to deliver next-generation
first-in-class immunotherapeutics:
- BiCKI® platform focused on immuno-oncology (IO) is a
bispecific fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced
BiCKI® candidate targeting anti-PD1xIL-7.
- Myeloid platform focused on optimizing the therapeutic
potential of myeloid cells in IO and immuno-inflammation (I&I).
OSE-230 (ChemR23 agonist mAb) is the most advanced candidate
generated by the platform, with the potential to resolve chronic
inflammation by driving affected tissues to tissue integrity.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com
Click and follow us on Twitter and LinkedIn
Forward-looking statements
This press release contains express or implied information and
statements that might be deemed forward-looking information and
statements in respect of OSE Immunotherapeutics. They do not
constitute historical facts. These information and statements
include financial projections that are based upon certain
assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of
historical trends, current economic and industry conditions,
expected future developments and other factors they believe to be
appropriate.
These forward-looking statements include statements typically
using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their
declensions and conjugations and words of similar import. Although
the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230622711602/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com +33 1 53 198 757 Nicolas Poirier Chief
Executive Officer nicolas.poirier@ose-immuno.com French Media:
FP2COM Florence Portejoie fportejoie@fp2com.fr +33 6 07 768
283
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Jun 2023 bis Jun 2024